title: New-onset atrial fibrillation after acute myocardial infarction and its relation to admission biomarkers (from the TRIUMPH registry).
abstract: Atrial fibrillation (AF) is an independent predictor of mortality after acute myocardial infarction (AMI). We analyzed the relation between biomarkers linked to myocardial stretch (NT-pro-brain natriuretic peptide [NT-proBNP]), myocardial damage (Troponin-T [TnT]), and inflammation (high-sensitivity C-reactive protein [hs-CRP]) and new-onset AF during AMI to identify patients at high risk for AF. In a prospective multicenter registry of AMI patients (from the Translational Research Investigating Underlying disparities in recovery from acute Myocardial infarction: Patients' Health status registry), we measured NT-proBNP, TnT, and hs-CRP in patients without a history of AF (n = 2,370). New-onset AF was defined as AF that occurred during the index hospitalization. Hierarchical multivariate logistic regression models were used to determine the association of biomarkers with new-onset AF, after adjusting for other covariates. New-onset AF was documented in 114 patients with AMI (4.8%; mean age 58 years; 32% women). For each twofold increase in NT-proBNP, there was an 18% increase in the rate of AF (odds ratio [OR] 1.18, 95% confidence interval [CI] 1.03 to 1.35; p <0.02). Similarly, for every twofold increase in hs-CRP, there was a 15% increase in the rate of AF (OR 1.15, 95% CI 1.02 to 1.30; p = 0.02). TnT was not independently associated with new-onset AF (OR 0.96, 95% CI 0.85 to 1.07; p = 0.3). NT-proBNP and hs-CRP were independently associated with new in-hospital AF after MI, in both men and women, irrespective of race. Our study suggests that markers of myocardial stretch and inflammation, but not the amount of myocardial necrosis, are important determinants of AF in the setting of AMI.
authors.affiliation: Division of Cardiology, Department of Medicine, Emory University, Atlanta, Georgia. Electronic address: Susmita.parashar@emory.edu.
authors.forename: Susmita
authors.initials: S
authors.lastname: Parashar
authors.forename: Danesh
authors.initials: D
authors.lastname: Kella
authors.forename: Kimberly J
authors.initials: KJ
authors.lastname: Reid
authors.forename: John A
authors.initials: JA
authors.lastname: Spertus
authors.forename: Fengming
authors.initials: F
authors.lastname: Tang
authors.forename: Jonathan
authors.initials: J
authors.lastname: Langberg
authors.forename: Viola
authors.initials: V
authors.lastname: Vaccarino
authors.forename: Michael C
authors.initials: MC
authors.lastname: Kontos
authors.forename: Renato D
authors.initials: RD
authors.lastname: Lopes
authors.forename: Michael S
authors.initials: MS
authors.lastname: Lloyd
mesh_terms: D001281:Atrial Fibrillation / Q000097:blood / Q000453:epidemiology* / Q000209:etiology; D015415:Biomarkers / Q000097:blood*; D016001:Confidence Intervals; D003955:Diagnostic Tests, Routine / Q000379:methods; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D009203:Myocardial Infarction / Q000097:blood / Q000150:complications*; D016017:Odds Ratio; D010343:Patient Admission; D011379:Prognosis; D011446:Prospective Studies; D012042:Registries; D014481:United States / Q000453:epidemiology
chemical_list: D015415:Biomarkers